Novartis pelacarsen trial fails to meet primary endpoint

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. TTAN
2. BRZE
3. CHYM
4. USO
5. QCOM
6. IRT
7. UNFI
8. SPY
9. ASO
10. EVMN

Go back to Novartis pelacarsen trial fails to meet primary endpoint
NOVARTIS AG (NYSE: NVS) Delayed: 137.70 --0 (-0%)
Previous Close $137.70    52 Week High $89.15 
Open $137.70    52 Week Low $69.84 
Day High $137.70    P/E N/A 
Day Low $137.70    EPS $0.00 
Volume 78,035